Company Management

PharmNovo

Biotechnology Research Se 10 employees

Employees: 10
Contacts: 3
Emails: 3
Phones: 1

pharmnovo.com LinkedIn Crunchbase

PharmNovo Overview

Headquarters: Se
Phone Number: Available in AeroLeads
Website: pharmnovo.com
Industry: Biotechnology Research
Employees: 10
Founded: 2008
Funding: 16.3M
Company Email: Available in AeroLeads
NAICS: Research and Development in Biotechnology (except Nanobiotechnology)

Keywords

CNS Neurology Chronic Pain Treatment BioPharma Bioscience Chemistry Biotechnology Pharmacology Proteins DOR agonists Delta opioid receptor

About PharmNovo

PharmNovo AB is a clinical-stage pharmaceutical company focused on developing safe and effective drugs for neuropathic pain. In this area, there is currently a lack of sufficient treatments. The company’s drug candidate, PN6047, effectively reduces neuropathic pain in animal models and the findings from the Phase I trial show that PN6047 is safe and well-tolerated at the doses tested, with no serious adverse events reported. Furthermore, PN6047 exhibited none of the adverse events typically associated with the conventional opioids like oxycodone and morphine, such as respiratory depression, constipation, itching, or signs of abuse potential. This validates the unique preclinical profile of PN6047, which shows that it acts extremely selectively on the delta opioid receptor distinguishing it fundamentally from conventional opioids that target the mu opioid receptor. PN6047 is Phase II ready!

PharmNovo Contact Details

People in AeroLeads: 3
With contact data: 3
Email contacts: 3; 100.0% coverage
Phone contacts: 1; 33.3% coverage

PharmNovo Org Chart

Sample employees and titles

Name	Title	Location	Contact
Johan Dighed		Stockholm County, Sweden	Email Phone
Helen Pettersson	Investment Manager På Almi Invest Syd	Sweden	Email
Bengt Von Mentzer	Chief Scientific Advisor, Founder at Pharmnovo	Greater Gothenburg Metropolitan Area, Sweden	Email